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Abstract
Background: Atazanavir (ATV) not boosted by ritonavir (uATV) has been frequently used in the past for switching
combination antiretroviral therapy (cART). However, the clinical outcomes and predictors of such strategy are unknown.
Methods: An observational study was carried out on the Italian MASTER, selecting HIV infected patients on cART
switching to an uATV-containing regimen. Baseline was set as the last visit before uATV initiation. In the primary
analysis, a composite clinical end-point was defined as the first occurring of any condition among: liver, cardiovascular,
kidney, diabetes, non AIDS related cancer or death events. Incidence of AIDS events and incidence of composite
clinical end-point were estimated. Kaplan-Meier and multivariable Cox regression analysis were used to assess
predictors of the composite clinical end-point.
Results: 436 patients were observed. The majority of patients were males (61.5%) and Italians (85.3%), mean age was
42.7 years (IQR: 37.7–42), the most frequent route of transmission was heterosexual intercourse (47%), followed by
injection drug use (25%) and homosexual contact (24%); the rate of HCV-Ab positivity was 16.3%. Patients were
observed for a median time of 882 days (IQR: 252-1,769) under uATV. We recorded 93 clinical events (3 cardiovascular
events, 20 kidney diseases, 33 liver diseases, 9 non AIDS related cancers, 21 diabetes, 7 AIDS events), and 19 deaths,
accounting for an incidence of 3.7 (composite) events per 100 PYFU. At multivariable analysis, factors associated with
the composite clinical end-point were intravenous drug use as risk factor for HIV acquisition vs. heterosexual
intercourses [HR: 2.608, 95% CI 1.31–5.19, p = 0.0063], HIV RNA per Log10 copies/ml higher [HR: 1.612, 95% CI 1.278–2.
034, p < 0.0001], number of switches in the nucleoside/nucleotide (NRTI) backbone of cART (performed to compose
the uATV regimen under study or occurred in the past) per each more [HR: 1.085, 95% CI 1.025–1.15, p = 0.0051], Fib-4
score per unit higher [HR: 1.03, 95% CI 1.018–1.043, p < 0.0001] and Neutrophil/lymphocytes ratio (NLR inflammation
score) per Log10 higher [HR: 1.319, 95% CI 1.047–1.662, p = 0.0188].
Conclusions: Intravenous drug users with high HIV RNA, high Fib-4 levels and more heavily exposed to antiretroviral
drugs appeared to be more at risk of clinical events. Interestingly, high levels of inflammation measured through NLR,
were also associated with clinical events. So, these patients should be monitored more strictly.
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Background
Atazanavir (ATV) is a protease inhibitor (PI) for the treat-
ment of HIV infection, prescribed with ritonavir (atazana-
vir/ritonavir, ATV/r) in combination antiretroviral therapy
(cART) [1–4]. Differently from other PIs, ATV not boosted
by ritonavir (unboosted ATV, uATV) has been rather
frequently used in the past as an off-label switching option
[5, 6], for toxicity reasons [7, 8]. Previous studies indicated
safety and effectiveness of uATV prescription in selected
cART experienced patients, with undetectable HIV RNA
and without drug resistances [9]. This is why regimens in-
cluding uATV have been experimented with and were used
in clinical practice [6], and subsequently uATV prescription
has been formally approved in the meantime by European
Medicine Agency (EMA) and by Italian National Health
authorities in 2014. At the same time, national guidelines
recommended caution because of the lower genetic barrier
of regimens including uATV [10].
Clinical outcome of patients receiving ATV (and par-
ticularly of those received uATV) is still not completely
clear. In a previous study of the Italian MASTER cohort
[11], patients treated with ATV/r more frequently
achieved a composite outcome of success (HIV RNA <500
copies/mL, no AIDS events, CD4 + T cell count >500 cell/
mm3) than patients prescribed other PIs [12] and reported
a lower probability of switching the regimen than patients
treated with other PIs [12].
However, there are some unknowns about cardiovas-
cular risk and renal and liver profile of patients treated
with uATV. Firstly, a moderate increase of lipid values
(total cholesterol, HDL and LDL fractions, triglycerides)
has been reported in patients prescribed ATV/r [13, 14].
Similarly, the expected increase in cardiovascular risk
[15] was not confirmed by previous studies [16–18]. A
recent study of the Italian MASTER cohort reported
that the increased total cholesterol was balanced by the
increased HDL fraction in patients prescribed ATV/r or
uATV [19] and other studies observed a less impact on
lipid profile in patients prescribed uATV [20].
Some degrees of acute and chronic interstitial
nephritis, crystal deposition and nephrolithiasis were de-
scribed when ATV/r was co-administered with other po-
tentially nephrotoxic drugs, as tenofovir (TDF) [21–23].
However, an improvement of filtration rate in patients
prescribed ATV/r or uATV was reported, either after
switching to a regimen without TDF [19] or in patients
prescribed ATV/r as a part of simplification regimens
[13, 14]. Therefore, other factors than use of ATV may
be involved in renal failure development.
Liver toxicity is a well-known side effect of ATV/r, so
prescription of uATV is often adopted in case of severe
hyperbilirubinaemia and cholelitiasis [7]. However, ef-
fects of uATV prescription on liver fibrosis progression
are not yet known.
Further, an increased risk of clinical events was associ-
ated with systemic inflammation levels in HIV infected
patients. As recently described, neutrophil/lymphocyte
ratio (NLR) measured at baseline and during follow up
was independently associated with incidence of cardio-
vascular events [24], and both NLR and platelet/lympho-
cyte ratio (PLR) have been found to be associated with
risk of death in patients with solid cancer, in general
population and HIV positive subjects [25].
Lastly, among proposed serum non-invasive bio-
markers of liver fibrosis, the Fib-4 score has been vali-
dated both in HIV/HCV co-infected and in HIV mono-
infected patients and it was a reliable driver of both liver
fibrosis progression and clinical events [26, 27].
The goals of present study were: (i) to estimate the risk
of clinical progression (including both AIDS and non
AIDS related morbidities, and death) in patients pre-
scribed uATV; (ii) to explore possible predictors of the
aforementioned outcomes, including systemic inflamma-
tion scores.
Methods
Characteristics of the Italian MASTER cohort
The present study was conducted including patients en-
rolled in the Italian MASTER cohort (MAnagement
Standardizzato di TErapia antiRetrovirale, Standardized
Management of Antiretroviral Therapy), a longitudinal
multicenter cohort including patients in nine referral cen-
ters throughout Italy (http://www.mastercohort.it) [11]. Pa-
tients’ data are recorded on a common electronic clinical
chart software (Health & Notes 3.5W, Healthware S.p.A.,
Naples, Italy) employed by all participating Centers. The
electronic clinical chart is used to record data of patients at
each visit and periodically revised and updated. All partici-
pant subjects signed written informed consent and each
center obtained approval by its Ethics Committee.
Study design
An observational study including HIV infected patients
switching to uATV was performed. All patients were 18
years old or more. Patients were included in the study if
received uATV from 2000 to 2015. Subjects included in
the study were all experienced to antiretroviral therapy.
Baseline was defined as the last evaluation before uATV
prescription. Patients were followed from baseline (date
of the last visit or exam evaluation before uATV pre-
scription) to the time of death, switching from uATV to
another regimen, or to the last available visit. The obser-
vation was interrupted also when patients were lost to
follow up. Patients with any renal, liver, cardiovascular
events or non AIDS related cancers before or at switch
to uATV were excluded from the present study. A com-
posite end-point (the first occurring of these conditions:
liver, cardiovascular, kidney, diabetes, non AIDS related
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cancer or death events). Renal disease was defined as es-
timated glomerular filtration rate (eGFR) ≤60 ml/min
calculated using Chronic Kidney Disease Epidemiology
(CKD-EPI) formula [28], an additional measurement of
eGFR within 90 days was acquired to confirm renal im-
pairment. Clinical events of patients were recorded on
an electronic clinical chart and reported following a
standard classification [11]. Cardiovascular events in-
cluded diagnosis of acute myocardial infarction, stroke,
transient ischemic attack, angina pectoris, coronary by-
pass, angioplasty, chronic occlusive arterial disease,
hypertension. Liver diseases included: hyperbilirubine-
mia (>2.5 mg/dl), liver fibrosis stage ≥ F3, diagnosis of
liver cancer. Diabetes was defined as fasting glucose
≥126 mg/dl or oral anti diabetes therapy or insulin pre-
scription. Discontinuation of uATV was defined as
uATV interruption or ATV/r prescription. Causes of
uATV discontinuation were categorized as: virological
failure, toxicity, simplification, other. A sensitivity ana-
lysis limited to patients who reported <4 changes of
therapy in the nucleoside/nucleotide (NRTI) backbone
(at baseline or in the past) was conducted, in order to
exclude potential confounders due to multiple cART
switches and multiple virological failures.
Data collection
Baseline data collected included age, gender, nationality,
risk factors for HIV acquisition, HBV and/or HCV co-
infections, number of AIDS events, HIV RNA, CD4+ T
cell count, ATV/r exposure, cART switches occurred for
the backbone. The following parameters were also col-
lected during the follow-up if available: CD4+ T-cell
count, HIV RNA, bilirubin levels, γ-glutamyl transferase
(γGT) levels, alanine transaminase (ALT) and aspartate
transaminase (AST) levels, total and fractioned choles-
terol, triglycerides, serum glucose, serum creatinine,
platelet count, albumin, blood count, C reactive protein
and coagulation markers.
Liver fibrosis estimated by Fib-4 formula [29], eGFR,
body mass index (BMI) and systemic inflammation scores
(GPS-Glasgow Prognostic Score; mGPS-modified Glas-
gow Prognostic Score; NLR and PLR) were calculated at
baseline and during the follow up using data collected at
each time point. Clinical events (AIDS, diabetes, non
AIDS related cancers, cardiovascular events, renal and
liver diseases), discontinuations of uATV and deaths were
recorded at baseline and at each time-point.
Statistical analysis
Incidence of AIDS and non-AIDS clinical events and of
the composite end-point were calculated. Kaplan-Meier
analysis was performed to estimate probability of being
event-free during follow up. Cox regression analysis, uni-
variate and multivariable analyses (with bi-directional
stepwise selection driven by Akaike Information Criterion,
AIC), were used to assess predictors of composite clinical
end-point. Data collected at baseline and during the
follow-up, were input in the models as time updated vari-
ables. All analyses were performed using R, the language
for statistical computing (https://www.r-project.org/).
Results
Baseline characteristics of patients
Four hundred and thirty-six patients were selected (see
Table 1). The majority of patients were males (61.5%)
and Italians (85.3%). Mean age was 42.7 years (IQR:
37.7–42). The most frequent risk factor for HIV trans-
mission was heterosexual intercourse (47%), followed by
injection drug use (25%) and homosexual contact (24%).
The rate of positive HCV-Ab was 16.3%. All patients
were previously exposed to antiretroviral drugs, includ-
ing protease inhibitors, before switching to uATV.
Clinical outcomes
Patients were observed for a median time of 882 days
(IQR: 252–1,769) under uATV. For the composite clinical
end-point, 40 and 30 patients contributed after day 200
and 300, respectively. Ninety three clinical events (3 car-
diovascular events, 20 kidney diseases, 33 liver diseases, 9
cancers, 21 diabetes, 7 AIDS events), and 19 deaths oc-
curred during the follow up. Eighty nine composite clin-
ical events were observed (Fig. 1). Causes of death were:
AIDS for 6/19 patients, cardiovascular event 1/19, non
AIDS related cancer 1/19, other reasons 11/19 patients.
An incidence of 3.7 events per 100 person-year of follow-
up (PYFU) was estimated. Three hundred eighty-six pa-
tients (88.5% of total subject enrolled) discontinued uATV
during the follow up. For uATV discontinuations, 48 and
36 patients contributed with data after 2000 and 3000
days, respectively. The cumulative incidence of discontin-
uations of uATV was 16.6 per 100 PYFU. Forty-seven per
cent patients switched to alternative drugs and 53%
patients were prescribed ATV/r. Fourteen percent of the
patients stopped uATV for toxicity, 19% for simplification,
15% for virological failure, 5% for patient’s choice, and
47% for other/unknown reasons including avoidance of
off label prescriptions in patients who did not have any
other reasons for stopping uATV.
Predictors of clinical outcomes
Incidence of the composite end point according to risk
factors for HIV acquisition, HIV RNA, Fib-4 score, and
number of NRTI switches in the cART backbone are
depicted in Fig. 2. At multivariable analysis (Table 2),
factors associated with the composite clinical end-point
were: intravenous drug use as risk factor for HIV acqui-
sition vs. heterosexual intercourses [HR: 2.608, 95%CI
1.31–5.19, p = 0.0063], HIV RNA per Log10 copies/ml
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higher [HR: 1.612, 95% CI 1.278–2.034, p < 0.0001],
switches of cART backbone (performed to compose the
uATV regimen under study or occurred in the past) per
number of switches higher [HR: 1.085, 95% CI 1.025–
1.15, p = 0.0051], number of AIDS events prior or at
baseline [HR: 1.278, 95% CI 1.072–1.523, p = 0.0063],
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Table 1 Characteristics of the population at baseline
(Continued)
Age 42.72 (37.68-47.02)
BMI (Kg/m2) 23.64 (20.96-25.93)
CD4+ T cell count cells/mm3 486.4 (275.2-660)
Total cholesterol (mg/dl) 191.4 (153-225)
HDL 44.81 (35-51)
LDL 116.5 (90.75-136)
Triglycerides (mg/dl) 183.3 (89-221)
Serum glucose (mg/dl) 88.89 (82-97)
Bilirubin (mg/dl) 0.817 (0.4-1.01)
γGT (IU/L) 63.38 (20-62)
eGFR (mL/min/1.73 m2) 101.9 (90.28-114.2)
Number of switches in the NRTI backbone 4 (2-8)
Abbreviations: N number, HIV human immuno-deficiency virus, AIDS acquired
immune deficiency syndrome, MSM men have sex with men, IDU intravenous
drug use, HCV Ab hepatitis C virus antibodies, HBsAg Hepatitis B virus surface
antigen, Fib-4 fibrosis four score, PI proteases inhibitor, cART combination
antiretroviral therapy, γGT γ-glutammil-transpeptidase, BMI body mass index,
eGFR estimated glomerular filtration rate, NNRTI Non-Nucleoside Reverse
Transcriptase Inhibitors, NRTI Nucleoside Reverse Transcriptase Inhibitors, ABC:
abacavir, IQR interquartile range
Fig. 1 Kaplan-Meier estimation of probability of combined clinical
outcome. (Dashed lines represent 95% confidence intervals)
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serum glucose levels [HR: 1.034, 95%CI 1.026–1.042,
p < 0.0001], γGT levels [HR: 1.004, 95%CI 1.003–
1.005, p < 0.0001], Fib-4 score values per unit higher
[HR: 1.030, 95%CI 1.018–1.043, p < 0.0001] and NLR
score values per unit higher [HR: 1.002, 95%CI
1.001–1.004, p = 0.003]. Patients with homo-bisexual
intercourses as risk factor for HIV acquisition with
respect to heterosexual [HR: 0.379, 95%CI 1.402–
5.449, p = 0.003], LDL cholesterol [HR: 0.994, 95%CI
0.989-1, p = 0.0377] and eGFR [HR: 0.96, 95%CI
0.947–0.972, p < 0.0001] values per unit higher showed
a significant lower risk of composite clinical outcome.
Also, NLR values per Log10 higher [HR: 1.179, 95%CI
1.048–1.325, p = 0.006] showed statistically significant as-
sociations with uATV discontinuation (any causes). When
the analysis was performed in a subset of 219 patients who
reported <4 cART changes in the NRTI backbone (at base-
line or in the past), 35 composite events were observed ac-
counting for a cumulative incidence of 0.3 per 100 PYFU.
In this analysis, the association of NLR with the composite
clinical outcome was not statistically significant at univari-
ate analysis [HR: 0.999, 95%CI 0.992-1, p = 0.79], so it was
not included in the multivariable model. At multivariable
analysis, factors associated with the composite clinical
end-point were higher triglycerides levels [HR: 1.003,
95%CI 1.001-1.004, p < 0.0001], higher serum glucose [HR:
1.065, 95%CI 1.040–1.089, p < 0.0001] and Fib-4 score per
unit higher [HR: 1.108, 95%CI 1.048–1.172, p < 0.0001].
Discussion
This study evaluated long-term clinical outcomes of HIV
infected patients included in the Italian MASTER cohort
after switching to a simplification regimen which in-
cluded uATV. Findings of the present study are original
because, for the first time, we explored the possible asso-
ciation of both inflammation and liver fibrosis scores
with clinical events. Moreover, this is the first study
which evaluated long-term clinical outcomes in patients
treated with uATV.
High levels of inflammation are predictors of
clinical events and mortality in HIV infected patients
[30, 31]. In particular, studies from our cohort dem-
onstrated that NLR score is an independent predictor
of mortality for cancer [25, 32, 33], and cardiovascu-
lar events [24]. Moreover, it was demonstrated that
may predict death in patients with liver cirrhosis [34].
Herein we confirm that a high NLR is a predictor of
clinical events when a composite clinical outcome is
Fig. 2 Incidence of the composite outcome by risk factor for HIV acquisition (panel a), HIV RNA (panel b), number of switches in the nucleoside/
nucleotide backbone (panel c), and Fib-4 score (panel d). List of abbreviations MSM: men have sex with men, IDU: intravenous drug use, VL: HIV
RNA viral load, Fib4: fibrosis 4 score
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used in patients prescribed uATV. Conversely, we did
not observe any significant associations between clinical
outcome and GPS or PLR. So, probably, these scores (GPS
and PLR) are predictors of progression of disease and
mortality but only in specific subgroups of HIV infected
patients, such those with cancer [25, 32].
The fact that, in a subset of patients with experience of
<4 changes in the NRTI backbone, NLR was not signifi-
cantly associated with the composite clinical outcome may
indicate that this score is more reliable in those who were
more heavily exposed to cART, with a longer disease his-
tory, and with a greater risk of complications. Therefore,
our results suggest that NLR warrants more attention and
should be measured in HIV infected patients, especially in
the most fragile, even when they are treated with “meta-
bolic friendly” regimens (such as cART including uATV).
In the present study, we found that intravenous drug
use and higher γGT levels (that may be considered as
a proxy for alcohol abuse [35]) are associated with the
composite clinical outcome. Also, higher levels of
serum glucose were associated with clinical events.
These findings are not unexpected because it is well
known that life-style factors, such as nutritional habits,
alcohol abuse, intravenous drug use or smoking exert
an important role for the risk of clinical events even
in HIV infected patients [27, 36–39]. So, we confirm
that targeted interventions to correct these modifiable
risk factors should be prioritized in HIV infected
patients to reduce risk of clinical events even when
more “metabolic friendly” regimens are prescribed.
The Fib-4 score is a reliable marker of liver fibrosis
progression and clinical events in HIV infected patients
[26, 27]. Indeed, we also found a statistically significant as-
sociation of higher Fib-4 scores with the composite clinical
outcome. Hence, our results suggest that patients treated
with uATV with higher estimated liver fibrosis stage should
be considered more at risk for clinical events. This is par-
ticularly applied to patients co-infected with HCV, for
whom uATV was one of the preferred regimens [7, 8], and
to those with higher NLR. Overall, these results reinforce
the importance of eradicating HCV as it is the main driver
of liver fibrosis progression, to reduce both liver complica-
tions and non-AIDS related co-morbidities, especially if
Fib-4 and NLR remain elevated.
Results of our study are affected by several limitations.
First, high incidence rates of uATV discontinuations (in
most cases for “administrative” reasons to reduce off-label
prescriptions) may have reduced the length of observation
and, therefore, the statistical power of the study may have
been limited further. However, the impact of NLR was
demonstrated on the risk of both clinical complications
and discontinuations of uATV.
Second, our study did not include a control group.
Clearly, a control group would be of value, however, we be-
lieve that comparison with other cART regimens is not rec-
ommended in this study. Indeed, the main inclusion
Table 2 Univariate and multivariable analyses for composite clinical outcome
Univariate analysis Multivariable analysis (stepwise AIC)
Variable HR (95% CI) p-value HR (95% CI) p-value
Risk factors for HIV acquisition
MSM vs. heterosexual transmission 0.547 (0.28-1.068) 0.0773 0.379 (0.174-0.828) 0.0149
IDU vs. heterosexual transmission 2.165 (1.383-3.388) 0.0007 2.608 (1.31-5.19) 0.0063
Log10 HIV RNA (copies/mL) 1.516 (1.264-1.818) <0.0001 1.612 (1.278-2.034) <0.0001
LDL cholesterol (mg/dl) 0.995 (0.99-1.001) 0.0819 0.994 (0.989-1) 0.0377
Serum glucose (mg/dl) 1.026 (1.02-1.033) <0.0001 1.034 (1.026-1.042) <0.0001
γGT (IU/L) 1.003 (1.002-1.004) <0.0001 1.004 (1.003-1.005) <0.0001
eGFR (mL/min/1.73 m2) 0.968 (0.956-0.98) <0.0001 0.959 (0.947-0.972) <0.0001
Fib-4 1.033 (1.022-1.043) <0.0001 1.03 (1.018-1.043) <0.0001
Log10 NLR 1.31 (1.084-1.582) 0.0052 1.319 (1.047-1.662) 0.0188
Co-infections with hepatitis viruses
HBsAg unknown vs. HBsAg negative 1.067 (0.612-1.86) 0.82 2.525 (1.055-6.043) 0.0374
HCV Ab unknown vs. HCV Ab negative 1.495 (0.907-2.466) 0.1148 0.376 (0.164-0.86) 0.0205
Number of switches in the NRTI backbone 1.08 (1.037-1.125) 0.0002 1.085 (1.025-1.15) 0.0051
Number of AIDS events 1.205 (1.089-1.334) 0.0003 1.278 (1.072-1.523) 0.0063
HR hazard ratio, AIC Akaike Information Criterion, HIV human immuno-deficiency virus, AIDS acquired immune deficiency syndrome, MSM men have sex with men, IDU
intravenous drug use, HCV Ab hepatitis C virus antibodies, HBsAg Hepatitis B virus surface antigen, Fib-4 fibrosis four score, PI proteases inhibitor, cART combination
antiretroviral therapy, γGT γ-glutammil-transpeptidase, eGFR estimated glomerular filtration rate, NRTI Nucleoside/nucleotide reverse transcriptase inhibitors, CI
confidence interval, NLR neutrophil/lymphocytes ratio, HR hazard ratio, Fib-4 fibrosis 4 score
For quantitative variables, HR indicates the risk for each unit increase
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criteria uATV prescription; extending the patients’ selection
to other cART types would require an adjustment based on
the cART type. The cART effect may be so large to wash
out the predictors of clinical events that we are interested
in for the subpopulation of uATV. Nonetheless, we
recognize the importance of comparing event rates with
other regimens. An option could have been to match the
uATV population for baseline characteristics. But finding
suitable controls is difficult (if not impossible). Indeed, pa-
tients prescribed uATV in the past had much different
characteristics with respect to patients treated with alterna-
tive regimens: in clinical practice Italian physicians tended
to prescribe uATV in those with a higher rate or risk of co-
morbidities, confections with viral hepatitis or intolerance
to ritonavir as a booster. Moreover, it is difficult to set an
appropriate baseline for the control group (i.e. patients with
similar characteristics should have changed one or more
drugs after a comparable time period, treatment initiation,
or occurrence of certain adverse event). If the control is not
suitable we would have introduced several confounder-by-
indication biases.
Third, albeit alternative regimens are preferred over
uATV when metabolic or liver complications are of con-
cern, our results (especially the potential impact of per-
sisting inflammatory state estimated through NLR) may
be of general interest, provoking further investigations.
Since uATV may have a smaller effect on residual HIV
RNA which may increase, in its turn, levels of inflamma-
tion, it is important conduct further studies in patients
receiving different cART regimens.
Conclusions
This work showed that NLR score is associated with clinical
events in patients prescribed uATV, especially if they were
intravenous drug users with uncontrolled HIV RNA, higher
liver fibrosis stages, high γGTand serum glucose levels, and
more heavily pre-treated with cART. In conclusion, the role
of NLR in predicting the risk of non AIDS related compli-
cations and mortality should be investigated in further
studies, particularly in most fragile patients (either for HCV
co-infection or metabolic complications) such as those who
were usually treated with uATV in clinical practice.
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